With Gilead’s Reasonableness Standard, Side Effects May Vary

Key Takeaways

• California Supreme Court scrutinizes “duty to commercialize safer drug” theory
• Plaintiffs struggle to define “reasonable” R&D decisions under the proposed duty
• Court highlights conflict with existing patent exclusivity and FDA approval processes
• Reversal would reaffirm product-defect requirement as sole basis for drug liability
• Outcome could curb future lawsuits targeting pharma R&D choices

Pulse Analysis

The Gilead Tenofovir litigation has thrust a contentious legal concept into the spotlight: whether California law can impose a duty on pharmaceutical companies to commercialize a safer, equally effective drug. Plaintiffs argue that Gilead knew a less toxic formulation of Tenofovir existed and should have brought it to market sooner. Their theory hinges on a “reasonable” standard for R&D choices, but the Supreme Court justices repeatedly asked for concrete metrics, exposing the difficulty of translating scientific judgment into a legal duty.

Legal scholars note that the proposed duty collides with the entrenched patent and regulatory architecture that already governs drug development. Patent law grants a finite exclusivity period that begins at filing, not at market launch, creating a built‑in incentive to bring innovations to patients promptly. Overlaying a tort‑based requirement would effectively hand juries a veto over complex, high‑cost R&D decisions, undermining the predictability that the FDA approval process and the patent system provide. The court’s discomfort reflects a broader reluctance to let case‑by‑case litigation dictate the timing of medical breakthroughs.

If the court reverses the appellate ruling, it will reaffirm the product‑defect requirement as the exclusive pathway for pharmaceutical liability, limiting plaintiffs to traditional design‑defect claims. This outcome preserves the status quo, ensuring that innovators can allocate resources based on scientific merit and market considerations rather than fear of retroactive legal judgments. For the industry, the decision serves as a safeguard against a wave of lawsuits that could stifle investment in next‑generation therapies, while also reassuring investors that the legal environment remains conducive to sustained drug development.